Illumina Names Jonathan Seaton as Senior Vice President for Corporate & Bus. Development, Adding Further Clinical & Life Scie...
December 20 2016 - 9:00AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of
Jonathan Seaton as Senior Vice President for Corporate &
Business Development, further strengthening its executive team as
the company continues reinforcing the foundation for long-term
growth. Jonathan will join Illumina on January 3, 2017.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161220005239/en/
Jonathan Seaton (Photo: Business
Wire)
“Jonathan is a strong leader with an established track record of
successful strategic planning and business development in the
clinical and life sciences space,” said Marc Stapley, Executive
Vice President and Chief Administrative Officer of Illumina. “The
proven critical thinking he brings to Illumina coupled with his
comprehensive understanding of the markets we address make him a
great addition to our executive team.”
Jonathan will be responsible for global business development
activities, including strategic commercial deals, mergers and
acquisitions, licensing and partnerships. He joins Illumina from
Becton, Dickinson and Company where he was Vice President and Head
of Strategy and Business Development for the Life Sciences segment.
He previously held leadership roles at F. Hoffman-La Roche, Roche
Tissue Diagnostics, LS9, and several consulting firms and
investment banks. Jonathan studied medicine at the University of
Manchester, received a BSc degree in Molecular Biology and
Biochemistry from the University of Durham, and an MBA from the
Saïd Business School at the University of Oxford.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties. Examples of forward-looking statements
include, but are not limited to, statements we make regarding the
expected availability dates for new products and services and FDA
submission dates and intentions for certain products and services.
Important factors that could cause actual results to differ
materially from those in any forward-looking statements include
challenges inherent in developing, manufacturing, and launching new
products and services, and the other factors that are detailed in
our filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161220005239/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Eric Endicott,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024